1. Home
  2. PLNT vs NAMS Comparison

PLNT vs NAMS Comparison

Compare PLNT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Planet Fitness Inc.

PLNT

Planet Fitness Inc.

HOLD

Current Price

$53.31

Market Cap

4.0B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.66

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLNT
NAMS
Founded
1992
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.1B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PLNT
NAMS
Price
$53.31
$34.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
$107.46
$46.75
AVG Volume (30 Days)
1.8M
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,324,144,000.00
N/A
Revenue This Year
$19.22
$17.96
Revenue Next Year
$11.66
$540.65
P/E Ratio
$38.47
N/A
Revenue Growth
12.06
N/A
52 Week Low
$37.03
$20.53
52 Week High
$114.47
$42.21

Technical Indicators

Market Signals
Indicator
PLNT
NAMS
Relative Strength Index (RSI) 52.14 61.14
Support Level $49.36 $33.83
Resistance Level $54.47 $37.27
Average True Range (ATR) 1.75 1.53
MACD 0.53 0.57
Stochastic Oscillator 80.16 79.16

Price Performance

Historical Comparison
PLNT
NAMS

About PLNT Planet Fitness Inc.

Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: